384 related articles for article (PubMed ID: 19435366)
1. Rational design, synthesis, and pharmacological properties of new 1,8-naphthyridin-2(1H)-on-3-carboxamide derivatives as highly selective cannabinoid-2 receptor agonists.
Manera C; Saccomanni G; Adinolfi B; Benetti V; Ligresti A; Cascio MG; Tuccinardi T; Lucchesi V; Martinelli A; Nieri P; Masini E; Di Marzo V; Ferrarini PL
J Med Chem; 2009 Jun; 52(12):3644-51. PubMed ID: 19435366
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis, and biological evaluation of new 1,8-naphthyridin-4(1H)-on-3-carboxamide and quinolin-4(1H)-on-3-carboxamide derivatives as CB2 selective agonists.
Manera C; Benetti V; Castelli MP; Cavallini T; Lazzarotti S; Pibiri F; Saccomanni G; Tuccinardi T; Vannacci A; Martinelli A; Ferrarini PL
J Med Chem; 2006 Oct; 49(20):5947-57. PubMed ID: 17004710
[TBL] [Abstract][Full Text] [Related]
3. Rational design, synthesis and anti-proliferative properties of new CB2 selective cannabinoid receptor ligands: an investigation of the 1,8-naphthyridin-2(1H)-one scaffold.
Manera C; Saccomanni G; Malfitano AM; Bertini S; Castelli F; Laezza C; Ligresti A; Lucchesi V; Tuccinardi T; Rizzolio F; Bifulco M; Di Marzo V; Giordano A; Macchia M; Martinelli A
Eur J Med Chem; 2012 Jun; 52():284-94. PubMed ID: 22483967
[TBL] [Abstract][Full Text] [Related]
4. Novel 4-oxo-1,4-dihydroquinoline-3-carboxamide derivatives as new CB2 cannabinoid receptors agonists: synthesis, pharmacological properties and molecular modeling.
Stern E; Muccioli GG; Millet R; Goossens JF; Farce A; Chavatte P; Poupaert JH; Lambert DM; Depreux P; Hénichart JP
J Med Chem; 2006 Jan; 49(1):70-9. PubMed ID: 16392793
[TBL] [Abstract][Full Text] [Related]
5. New 1,8-naphthyridine and quinoline derivatives as CB2 selective agonists.
Manera C; Cascio MG; Benetti V; Allarà M; Tuccinardi T; Martinelli A; Saccomanni G; Vivoli E; Ghelardini C; Di Marzo V; Ferrarini PL
Bioorg Med Chem Lett; 2007 Dec; 17(23):6505-10. PubMed ID: 17942307
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and biological evaluation of 1,8-naphthyridin-4(1H)-on-3-carboxamide derivatives as new ligands of cannabinoid receptors.
Ferrarini PL; Calderone V; Cavallini T; Manera C; Saccomanni G; Pani L; Ruiu S; Gessa GL
Bioorg Med Chem; 2004 Apr; 12(8):1921-33. PubMed ID: 15051060
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and cytotoxic activity of carboxamide derivatives of benzo[b][1,6]naphthyridin-(5H)ones.
Deady LW; Rogers ML; Zhuang L; Baguley BC; Denny WA
Bioorg Med Chem; 2005 Feb; 13(4):1341-55. PubMed ID: 15670942
[TBL] [Abstract][Full Text] [Related]
8. CB2-selective cannabinoid receptor ligands: synthesis, pharmacological evaluation, and molecular modeling investigation of 1,8-Naphthyridin-2(1H)-one-3-carboxamides.
Lucchesi V; Hurst DP; Shore DM; Bertini S; Ehrmann BM; Allarà M; Lawrence L; Ligresti A; Minutolo F; Saccomanni G; Sharir H; Macchia M; Di Marzo V; Abood ME; Reggio PH; Manera C
J Med Chem; 2014 Nov; 57(21):8777-91. PubMed ID: 25272206
[TBL] [Abstract][Full Text] [Related]
9. New quinolone- and 1,8-naphthyridine-3-carboxamides as selective CB2 receptor agonists with anticancer and immuno-modulatory activity.
Manera C; Malfitano AM; Parkkari T; Lucchesi V; Carpi S; Fogli S; Bertini S; Laezza C; Ligresti A; Saccomanni G; Savinainen JR; Ciaglia E; Pisanti S; Gazzerro P; Di Marzo V; Nieri P; Macchia M; Bifulco M
Eur J Med Chem; 2015 Jun; 97():10-8. PubMed ID: 25935384
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and pharmacological evaluation of coumarin derivatives as cannabinoid receptor antagonists and inverse agonists.
Behrenswerth A; Volz N; Toräng J; Hinz S; Bräse S; Müller CE
Bioorg Med Chem; 2009 Apr; 17(7):2842-51. PubMed ID: 19278853
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and activity of 1,3,5-triphenylimidazolidine-2,4-diones and 1,3,5-triphenyl-2-thioxoimidazolidin-4-ones: characterization of new CB1 cannabinoid receptor inverse agonists/antagonists.
Muccioli GG; Wouters J; Charlier C; Scriba GK; Pizza T; Di Pace P; De Martino P; Poppitz W; Poupaert JH; Lambert DM
J Med Chem; 2006 Feb; 49(3):872-82. PubMed ID: 16451053
[TBL] [Abstract][Full Text] [Related]
12. Characterization of a cannabinoid CB2 receptor-selective agonist, A-836339 [2,2,3,3-tetramethyl-cyclopropanecarboxylic acid [3-(2-methoxy-ethyl)-4,5-dimethyl-3H-thiazol-(2Z)-ylidene]-amide], using in vitro pharmacological assays, in vivo pain models, and pharmacological magnetic resonance imaging.
Yao BB; Hsieh G; Daza AV; Fan Y; Grayson GK; Garrison TR; El Kouhen O; Hooker BA; Pai M; Wensink EJ; Salyers AK; Chandran P; Zhu CZ; Zhong C; Ryther K; Gallagher ME; Chin CL; Tovcimak AE; Hradil VP; Fox GB; Dart MJ; Honore P; Meyer MD
J Pharmacol Exp Ther; 2009 Jan; 328(1):141-51. PubMed ID: 18931146
[TBL] [Abstract][Full Text] [Related]
13. Indol-3-ylcycloalkyl ketones: effects of N1 substituted indole side chain variations on CB(2) cannabinoid receptor activity.
Frost JM; Dart MJ; Tietje KR; Garrison TR; Grayson GK; Daza AV; El-Kouhen OF; Yao BB; Hsieh GC; Pai M; Zhu CZ; Chandran P; Meyer MD
J Med Chem; 2010 Jan; 53(1):295-315. PubMed ID: 19921781
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, biological properties, and molecular modeling investigations of novel tacrine derivatives with a combination of acetylcholinesterase inhibition and cannabinoid CB1 receptor antagonism.
Lange JH; Coolen HK; van der Neut MA; Borst AJ; Stork B; Verveer PC; Kruse CG
J Med Chem; 2010 Feb; 53(3):1338-46. PubMed ID: 20047331
[TBL] [Abstract][Full Text] [Related]
15. N-Alkylidenearylcarboxamides as new potent and selective CB(2) cannabinoid receptor agonists with good oral bioavailability.
Ohta H; Ishizaka T; Tatsuzuki M; Yoshinaga M; Iida I; Tomishima Y; Toda Y; Saito S
Bioorg Med Chem Lett; 2007 Nov; 17(22):6299-304. PubMed ID: 17884496
[TBL] [Abstract][Full Text] [Related]
16. Synthesis, cannabinoid receptor affinity, molecular modeling studies and in vivo pharmacological evaluation of new substituted 1-aryl-5-(1H-pyrrol-1-yl)-1H-pyrazole-3-carboxamides. 2. Effect of the 3-carboxamide substituent on the affinity and selectivity profile.
Silvestri R; Ligresti A; La Regina G; Piscitelli F; Gatti V; Brizzi A; Pasquini S; Lavecchia A; Allarà M; Fantini N; Carai MA; Novellino E; Colombo G; Di Marzo V; Corelli F
Bioorg Med Chem; 2009 Aug; 17(15):5549-64. PubMed ID: 19595596
[TBL] [Abstract][Full Text] [Related]
17. Characterization of a novel and selective cannabinoid CB1 receptor inverse agonist, Imidazole 24b, in rodents.
Shearman LP; Stribling DS; Camacho RE; Rosko KM; Wang J; Tong S; Feng Y; Marsh DJ; Yu H; Guan X; Spann SK; Macneil DJ; Fong TM; Metzger JM; Goulet MT; Hagmann WK; Plummer CW; Finke PE; Mills SG; Shah SK; Truong Q; Van der Ploeg LH; Macintyre DE; Strack AM
Eur J Pharmacol; 2008 Jan; 579(1-3):215-24. PubMed ID: 18021763
[TBL] [Abstract][Full Text] [Related]
18. 1-Aryl-5-(1H-pyrrol-1-yl)-1H-pyrazole-3-carboxamide: an effective scaffold for the design of either CB1 or CB2 receptor ligands.
Piscitelli F; Ligresti A; La Regina G; Gatti V; Brizzi A; Pasquini S; Allarà M; Carai MA; Novellino E; Colombo G; Di Marzo V; Corelli F; Silvestri R
Eur J Med Chem; 2011 Nov; 46(11):5641-53. PubMed ID: 21996466
[TBL] [Abstract][Full Text] [Related]
19. Sulfonamide derivatives as new potent and selective CB2 cannabinoid receptor agonists.
Ohta H; Ishizaka T; Yoshinaga M; Morita A; Tomishima Y; Toda Y; Saito S
Bioorg Med Chem Lett; 2007 Sep; 17(18):5133-5. PubMed ID: 17643986
[TBL] [Abstract][Full Text] [Related]
20. Investigations on the 4-quinolone-3-carboxylic acid motif. 6. Synthesis and pharmacological evaluation of 7-substituted quinolone-3-carboxamide derivatives as high affinity ligands for cannabinoid receptors.
Pasquini S; De Rosa M; Ligresti A; Mugnaini C; Brizzi A; Caradonna NP; Cascio MG; Bolognini D; Pertwee RG; Di Marzo V; Corelli F
Eur J Med Chem; 2012 Dec; 58():30-43. PubMed ID: 23085772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
